BSX

PQUS · Weight decrease · 2d

Boston Scientific Corporation currently trades at $44.77, a mere 41% of its 52-week high, after suffering 30-day and 90-day returns of -8.8% and -39.4% respectively, alongside a -58.0% one-year return. This sustained underperformance likely prompted Pictet Asset Management's AI ranking system, governing the PQUS ETF, to re-evaluate the stock despite its 17.44% revenue growth and 14.87% ROE. Operating within a periodic rebalancing schedule for its ~165 US large-cap portfolio, the fund's AI initiated a reduction in BSX's weight, leading to the observed consecutive decreases from 0.97% on July 10th to 0.95% by July 12th. These adjustments align with the ETF's measured turnover style and its embedded sector-balance and concentration rules, responding to BSX's substantial market price decline.

weight 0.970% → 0.950% (-0.020 pp)·stock down 8.6% in the 30 days before

Jul 12·entry $44.65·now $43.77

PQUS · Weight decrease · 2d

With a PER of 18.81 and a 14.87% ROE, Boston Scientific Corporation exhibits financial characteristics that align with a US large-cap investment. However, the AI ranking system managing Pictet Asset Management's PQUS fund initiated a series of consecutive weight decreases for BSX, moving from 0.9700% on June 25th to 0.8700% by July 2nd. This measured portfolio adjustment by the AI system, which adheres to a measured turnover style, directly correlated with the stock trading near its 52-week low of $42.68, having experienced a -24.2% return over the prior 30 days. Despite a 17.44% revenue growth, the sustained price depreciation and the stock's position at 40% of its 52-week high evidently prompted the AI's re-evaluation and reduced allocation within the PQUS portfolio.

weight 0.940% → 0.870% (-0.070 pp)·stock down 5.3% in the 30 days before

Jul 2·entry $45.14·now $43.77

PQUS · Weight decrease · 2d

Boston Scientific Corporation's 17.44% revenue growth and 14.87% Return on Equity present a profile consistent with the US large-cap universe targeted by Pictet Asset Management's PQUS ETF. Despite these underlying metrics, the AI ranking system initiated a weight reduction for BSX from 0.9500% to 0.9300% on 2026-06-24, occurring as the stock was trading at $44.23, near its 52-week low following a -42.0% 90-day return. This action reflects the AI's re-evaluation within its sector-balance and concentration rules, indicating a diminished conviction that led to a net decrease in allocation from its prior stable level of 0.9500% down to 0.9400% by June 27th, indicative of a sustained re-positioning during the fund's periodic rebalancing.

weight 0.970% → 0.940% (-0.030 pp)·stock down 12.3% in the 30 days before

Jun 27·entry $43.48·now $43.77

PQUS · Weight decrease · 2d

Boston Scientific Corporation currently trades at $46.91, marking its 52-week low and representing only 43% of its high, following a -55.0% return over the past year and -17.0% in the last 30 days. This persistent downward price pressure likely influenced Pictet Asset Management's AI ranking system for its US large-cap universe during a recent periodic rebalance in PQUS. Despite BSX's 17.44% revenue growth and 14.87% ROE, the AI's re-evaluation, combined with the fund's sector-balance and concentration rules, prompted a consecutive weight decrease. This adjustment saw BSX's allocation in PQUS move from 1.0400% on June 12th to 0.9900% by June 14th, reflecting the AI's response to the stock's significant underperformance at its current valuation.

weight 1.040% → 0.990% (-0.050 pp)·stock down 11.6% in the 30 days before

Jun 14·entry $46.76·now $43.77

PQUS · Weight decrease · 4d

The AI ranking system employed by Pictet Asset Management for PQUS, which holds around 165 US large-cap stocks, evidently triggered the consecutive weight reduction for Boston Scientific. This pattern of decreases from late May suggests the fund’s periodic rebalance mechanism, as opposed to daily trading, adjusted the allocation based on recent stock performance. Boston Scientific's substantial 1-year return of -54.4% would have profoundly altered its standing within the AI's selection criteria, driving the methodical reduction in its portfolio presence. This move is consistent with PQUS's stated style of US large-cap investing with measured turnover, where underperforming assets are systematically re-evaluated.

weight 1.150% → 0.820% (-0.330 pp)·stock down 15.5% in the 30 days before

May 31·entry $47.98·now $43.77

PQUS · Weight decrease · 3d

stock down 15.5% in the 30 days before

May 30·entry $47.98·now $43.77

PQUS · Weight decrease · 2d

stock down 15.5% in the 30 days before

May 29·entry $48.31·now $43.77

PQUS · Weight decrease · 2d

stock down 16.9% in the 30 days before

May 17·entry $55.92·now $43.77

PQUS · Weight decrease · 2d

stock down 12.0% in the 30 days before

May 8·entry $53.93·now $43.77

PQUS · Weight decrease · 2d

stock down 9.2% in the 30 days before

Apr 29·entry $57.15·now $43.77

AIVL · Weight decrease · 2d

Boston Scientific Corporation currently trades at $44.23, hovering at 41% of its 52-week high and near the bottom of its $44.20 to $108.14 range, following a -55.7% decline over the past year. AIVL, which uses AI to distinguish genuine value from value traps within a US value-factor universe, systematically decreased its allocation to BSX, as shown by the recent shifts from 0.2206% to 0.2096%. Despite the substantial price drop, the AI’s continuous re-evaluation, based on fundamentals like margins and return on capital alongside valuation metrics such as P/E of 19.09 and P/B of 5.83, suggests it does not perceive sufficient underlying quality or future upside to warrant a higher weighting at this price level. This sustained reduction indicates that for AIVL’s AI, the stock's current price and metrics, including its 14.87% ROE and 17.44% revenue growth, align more with a value trap assessment rather than an undervalued asset requiring increased exposure.

weight 0.221% → 0.210% (-0.011 pp)·stock down 23.3% in the 30 days before

Jun 25·entry $44.20·now $43.77

AIVL · Weight decrease · 6d

The consecutive, daily decreases in Boston Scientific's weight within AIVL, moving from 0.2421% to 0.2122%, reflect a persistent re-evaluation by the AI management system. This pattern, occurring as BSX’s price plunged by 55.7% over the last year to its 52-week low of $44.33, signals the AI's discernment of a value trap rather than a genuine bargain. Despite a revenue growth of 17.44% and a 14.87% ROE, the AI likely flagged the lingering PBR of 5.83 and PER of 18.72, even at this reduced price, as still too high or indicative of future fundamental deterioration. This methodical reduction of exposure by WisdomTree’s AI-driven portfolio aligns with its mandate to identify and avoid such perceived mispricings within its US value-factor universe.

weight 0.242% → 0.212% (-0.030 pp)·stock down 21.8% in the 30 days before

Jun 22·entry $44.33·now $43.77

AIVL · Weight decrease · 5d

WisdomTree's AIVL, which employs an AI to distinguish genuine value from value traps within its approximately 100 US value stock holdings, initiated a series of weight reductions in Boston Scientific. The AI’s continuous assessment of fundamentals and valuation metrics likely flagged concerns about BSX, even as its price reached 42% of its 52-week high. Despite a 17.44% revenue growth, the company's relatively high PBR of 5.83 might have contributed to the AI's decision during a periodic rebalance to gradually decrease exposure, as the model aims for deep value. This pattern, observed through consecutive weight decreases from 0.2421% to 0.2183% over several days in June, suggests the system's active management to refine its value posture and avoid potential underperformers within its mandate.

weight 0.242% → 0.218% (-0.024 pp)·stock down 20.3% in the 30 days before

Jun 18·entry $45.29·now $43.77

AIVL · Weight decrease · 4d

WisdomTree's AIVL fund, employing AI to identify genuine value within its approximately 100-stock US value universe, reduced its weighting in Boston Scientific Corporation following a series of periodic evaluations. The AI's mandate to distinguish true value from value traps likely led it to reassess BSX, as certain valuation metrics, such as a PBR of 5.83, remained relatively high despite significant price depreciation. Even with BSX's 1-year return falling by 56.3% and the stock trading at 42% of its 52-week high, the model's comprehensive fundamental analysis (including margins, return on capital, and debt, alongside valuation) presumably signaled an increased risk or reduced value potential. This consecutive weight decrease, from 0.2420% to 0.2250%, indicates the AI's re-scoring of BSX led to a systematic adjustment during the fund's periodic rebalance cycle, aligning with its methodology of dynamically managing its pre-filtered US value pool.

weight 0.242% → 0.225% (-0.017 pp)·stock down 10.9% in the 30 days before

Jun 16·entry $46.92·now $43.77

AIVL · Weight decrease · 3d

AIVL, which employs AI to differentiate genuine value from value traps within its roughly 100 US value stock holdings, adjusted its exposure to Boston Scientific with a consecutive weight decrease ending June 12th at 0.2269%. This action suggests the AI’s fundamental and valuation analysis, which includes metrics like P/E and P/B, flagged BSX. Despite the stock’s current price being at its 52-week low and a 54.6% decline over the past year, the AI appears to have determined that its PBR of 5.83, for instance, still represents a valuation inconsistent with the fund’s definition of genuine value. This illustrates the strategy's focus on screening out value traps within its pre-filtered universe of value-factor names.

weight 0.242% → 0.227% (-0.015 pp)·stock down 11.6% in the 30 days before

Jun 12·entry $46.91·now $43.77

AIVL · Weight decrease · 2d

WisdomTree's AIVL, which employs AI to identify genuine value within its pre-filtered US value-factor pool, appears to have significantly re-evaluated its position in BSX. The precipitous reduction in holding from 1.6511% to 0.2371% suggests the AI's assessment of the stock's fundamental and valuation metrics, which inform its selection process for the ~100-stock portfolio, shifted during a periodic rebalance. This decisive action likely reflects a judgment that BSX's deteriorating price performance, including a -55.2% 1-year return, indicated a potential value trap rather than an undervalued opportunity. Minimal subsequent exposure and slight further adjustments suggest the AI's models continue to prioritize other opportunities within its rigorously screened universe.

weight 0.242% → 0.230% (-0.012 pp)·stock down 12.8% in the 30 days before

Jun 11·entry $47.17·now $43.77

AIVL · Weight decrease · 2d

weight 1.651% → 0.235% (-1.416 pp)·stock down 16.1% in the 30 days before

Jun 3·entry $47.69·now $43.77

AIVL · Sudden change · 1d

BSX’s PBR of 5.83 and PER of 19.72, even alongside 17.44% revenue growth and 14.87% ROE, presented valuation metrics that AIVL’s AI component would meticulously evaluate against its specific value-factor criteria. WisdomTree’s AI, tasked with distinguishing genuine value from value traps using fundamentals and valuation metrics like P/E and P/B, would assess if these multiples represented a sustainable value proposition within its ~100 US value stock universe. The significant reduction in AIVL’s weight from 1.6511% to 0.2371% between May 15 and June 1 occurred while BSX's price continued its prolonged decline, registering a -19.9% 30-day return and a -48.5% 90-day return, now trading at $47.68, only 44% of its 52-week high. This movement indicates the AI determined BSX no longer met the necessary risk-adjusted value thresholds for a substantial allocation within AIVL's portfolio, prompting the sharp decrease in holding.

weight 1.651% → 0.237% (-1.414 pp)·stock down 16.7% in the 30 days before

Jun 1·entry $47.98·now $43.77

AIVL · Weight decrease · 2d

stock down 13.6% in the 30 days before

May 11·entry $53.37·now $43.77

AIVL · Weight decrease · 2d

stock down 9.5% in the 30 days before

May 6·entry $56.00·now $43.77

AIEQ · Exit · 1d

Boston Scientific Corporation presented a PER of 18.81, PBR of 5.83, 17.44% revenue growth, and 14.87% ROE, figures that AIEQ’s fundamentals + sentiment hybrid style continuously evaluates. The fund’s complete removal of BSX on 2026-07-01 followed a reduction to 0.0900% the previous day, occurring as the stock traded at $43.06, near the bottom of its $42.68 to $108.14 52-week range. This swift divestment reflects AIEQ’s daily rebalancing and high-turnover, where IBM Watson NLP ingests a wide array of data including news, analyst notes, and social posts. The sustained negative price context, with a -24.2% 30-day return for the health care sector stock, likely influenced the AI's ranking and EquBot's risk overlay to exit the position from its 140-180 stock portfolio.

weight 0.090% → 0 (exited)·stock down 10.3% in the 30 days before

Jul 1·entry $43.06·now $43.77

AIEQ · Weight decrease · 2d

stock down 15.5% in the 30 days before

May 30·entry $47.98·now $43.77